Inhibition of CPT1a as a prognostic marker can synergistically enhance the antileukemic activity of ABT199

Targeting MCL-1 in hematologic malignancies: Rationale and progress

(2020) AndrewH. Wei et al.   BLOOD REVIEWS

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells

(2016) X. Niu et al.   CLINICAL CANCER RESEARCH

Venetoclax: First Global Approval

(2016) Emma D. Deeks   DRUGS

Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer

(2016) Q Qu et al.   Cell Death & Disease

BCL2 Inhibition by Venetoclax: Targeting the Achilles' Heel of the Acute Myeloid Leukemia Stem Cell?

(2016) V. A. Pullarkat et al.   Cancer Discovery

High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia

(2016) Jinlong Shi et al.   EBioMedicine

Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias

(2015) M. R. Ricciardi et al.   BLOOD

Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199

(2014) X Niu et al.   LEUKEMIA

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Thr 163 Phosphorylation Causes Mcl-1 Stabilization when Degradation Is Independent of the Adjacent GSK3-Targeted Phosphodegron, Promoting Drug Resistance in Cancer

(2012) Shanna K. Nifoussi et al.   PLoS One